The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study

被引:0
作者
Alexandra M. Mueller
Evangelia Liakoni
Cornelia Schneider
Theresa Burkard
Susan S. Jick
Stephan Krähenbühl
Christoph R. Meier
Julia Spoendlin
机构
[1] University of Basel,Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences
[2] University Hospital Basel,Hospital Pharmacy
[3] University of Bern,Clinical Pharmacology and Toxicology, Department of General Internal Medicine, Inselspital, Bern University Hospital
[4] Boston Collaborative Drug Surveillance Program,Division of Clinical Pharmacology and Toxicology
[5] Boston University School of Public Health,Department of Biomedicine
[6] University Hospital Basel,undefined
[7] University of Basel,undefined
来源
Journal of General Internal Medicine | 2021年 / 36卷
关键词
statin; myopathy; myalgia; adverse events; CPRD;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2639 / 2647
页数:8
相关论文
共 109 条
[1]  
Mach F(2020)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J. 41 111-188
[2]  
Baigent C(2015)Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Eur Heart J. 36 1012-1022
[3]  
Catapano AL(2009)Narrative review: statin-related myopathy Ann Intern Med. 150 858-868
[4]  
Stroes ES(2010)Statin myopathy: A review of recent progress Curr Opin Rheumatol. 22 644-650
[5]  
Thompson PD(2016)Muscle- and skeletal-related side-effects of statins: tip of the iceberg? Eur J Prev Cardiol. 23 88-110
[6]  
Corsini A(2010)Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment Drug Saf. 33 171-187
[7]  
Joy TR(2013)Intolerance to statins: Mechanisms and management Diabetes Care. 36 S325-S330
[8]  
Hegele RA(2019)Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components J Clin Med. 9 22-1849
[9]  
Mammen AL(1853)The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity Biochim Biophys Acta. 2015 1841-e164
[10]  
Amato AA(2007)Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study Atherosclerosis. 194 e154-1394